Intravenous Tocilizumab (IV tocilizumab) coverage
Customize your policy alerts
Sign up for Bluecross Idaho Policy 5.01.502 alerts
Get alerted when Policy 5.01.502 changes without checking for updates manually.
Monitor payer policy activity
Defines medical-benefit coverage, clinical criteria, and prior-authorization expectations for intravenous tocilizumab (including Actemra and listed biosimilars) for specified indications; applies to Blue Cross of Idaho members subject to their member-specific benefit plan.
Blue Cross of Idaho adopted changes effective 01/01/2026, including a policy statement about subcutaneous formulation and clarifications related to tuberculosis screening.
New policy added to prescription drug section.
tocilizumab is to be filled under the pharmacy benefit.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.